Key result
Glibenclamide completely abolished MAPD shortening during myocardial ischemia but not during KCl-induced hyperkalemia, indicating different K+ channels regulate MAPD in these states.
Why the study?
Does glibenclamide prevent the shortening of monophasic action potential duration during hyperkalemia or myocardial ischemia in anesthetized dogs?
Does glibenclamide prevent the shortening of monophasic action potential duration during hyperkalemia or myocardial ischemia in anesthetized dogs?
The shortening of monophasic action potential duration during myocardial ischemia is mainly dependent on the activation of K(ATP) channels, whereas shortening during hyperkalemia is not.
Supports K(ATP) role in canine ischemic MAPD shortening; hypothesis-generating and leaves clinical translation open.
The elevation of the myocardial extracellular potassium concentration ([K+]o) is known to shorten action potential duration, which may lead to the occurrence of arrhythmias. The aim of this study was to compare the mechanisms responsible for the shortening of monophasic action potential duration (MAPD) in hyperkalemic and myocardial ischemic hearts in anesthetized dogs. During a venous infusion of KCl for 5 min, [K+]o was increased and MAPD was significantly shortened. The ATP-sensitive K+ (K[ATP]) channel blocker glibenclamide did not affect the shortening of MAPD during KCl-infusion, indicating that K(ATP) channels are not involved in this mechanism. During 5-min occlusion of the left anterior descending coronary artery, [K+]o was increased, myocardial pH was decreased and MAPD was shortened. Glibenclamide completely abolished the shortening of MAPD, while partial elevation of [K+]o remained even in the presence of glibenclamide. This suggests that the shortening of MAPD is dependent mainly on the activation of K(ATP) channels. Both models in the present study demonstrate that different types of potassium channels are involved in the regulation of action potential duration.
No takes yet. Share an insight, caveat, or question.
Hamada et al. (1998) studied Hyperkalemia and myocardial ischemia. Glibenclamide vs. No glibenclamide was evaluated on Shortening of monophasic action potential duration (MAPD). Glibenclamide completely abolished MAPD shortening during myocardial ischemia but not during KCl-induced hyperkalemia, indicating different K+ channels regulate MAPD in these states.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: